↓ Skip to main content

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission

Overview of attention for article published in Biology of Blood & Marrow Transplantation, February 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
19 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission
Published in
Biology of Blood & Marrow Transplantation, February 2016
DOI 10.1016/j.bbmt.2015.08.035
Pubmed ID
Authors

Andrew J. Cowan, Philip A. Stevenson, Ryan D. Cassaday, Solomon A. Graf, Jonathan R. Fromm, David Wu, Leona A. Holmberg, Brian G. Till, Thomas R. Chauncey, Stephen D. Smith, Mary Philip, Johnnie J. Orozco, Andrei R. Shustov, Damian J. Green, Edward N. Libby, William I. Bensinger, Mazyar Shadman, David G. Maloney, Oliver W. Press, Ajay K. Gopal

Abstract

Autologous stem cell transplantation (ASCT) is standard therapy for mantle cell lymphoma (MCL) in remission following induction chemotherapy with the best results for patients in complete remission (CR). We hypothesized that evaluation of MRD prior to ASCT could further stratify outcomes for these patients. Patients with MCL who underwent ASCT in clinical CR between 1996 and 2011, with pretransplant MRD testing were eligible. Presence of a clonal IgH rearrangement, t(11;14) by PCR, or positive flow cytometry from blood or bone marrow was considered positive. An adjusted proportional hazards model for associations with progression-free (PFS) and overall survival (OS) was performed. Of 75 MCL patients in CR, 8 (11%) were MRD positive. MRD positivity was associated with shorter OS and PFS. The median OS for MRD-negative patients was not reached with 82% survival at 5 years, while for the MRD-positive patients was 3.01 years (hazard ratio [HR] 4.04, p = 0.009), with a median follow-up of 5.1 years. The median PFS for MRD-negative patients was not reached with 75 % PFS at 5 years, while for MRD-positive patients was 2.38 years (HR 3.69, p = 0.002). MRD positivity is independently associated with poor outcome following ASCT for MCL patients in CR.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 5%
United States 1 5%
Unknown 17 89%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 47%
Student > Doctoral Student 3 16%
Lecturer > Senior Lecturer 2 11%
Professor > Associate Professor 2 11%
Other 1 5%
Other 2 11%
Readers by discipline Count As %
Medicine and Dentistry 14 74%
Agricultural and Biological Sciences 3 16%
Unspecified 2 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2015.
All research outputs
#10,000,114
of 12,494,204 outputs
Outputs from Biology of Blood & Marrow Transplantation
#1,698
of 2,217 outputs
Outputs of similar age
#165,493
of 241,149 outputs
Outputs of similar age from Biology of Blood & Marrow Transplantation
#70
of 78 outputs
Altmetric has tracked 12,494,204 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,217 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 9th percentile – i.e., 9% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,149 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 78 others from the same source and published within six weeks on either side of this one. This one is in the 5th percentile – i.e., 5% of its contemporaries scored the same or lower than it.